单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）疗法用于肿瘤治疗的创新策略开发
英文原题：Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment.
查看英文原题
Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症是全球死亡的主要原因，因此对有效癌症治疗策略的需求仍十分迫切。过继转移TIL（肿瘤浸润淋巴细胞）是恶性肿瘤免疫治疗的一种有前景方法。多项严格临床试验已证实 TIL 疗法的临床安全性和有效性。然而，TIL 输注诱导抗肿瘤应答的疗效仅见于部分癌症患者。因此，亟需开发创新策略以提高 TIL 疗法的有效性。本综述系统总结并分析 TIL 疗法的发展历程，并从独特角度探讨如何增强 TIL 多维度抗肿瘤能力。本文的见解和结论有望提高 TIL 疗法疗效并加速其发展。
展开英文摘要原文
Cancer is the main cause of global mortality, and thus far, effective therapeutic strategies for cancer treatment are in high demand. Adoptive transfer of tumor infiltrating lymphocytes (TILs) represents a promising avenue in immunotherapy for the management of malignancies. The clinical safety and efficacy of TIL based therapy have been established through numerous rigorous clinical trials.
However, the efficacy of TIL infusion in inducing an anti tumor response is limited to a subset of clinical patients with cancer.
Therefore, there is an urgent need to develop innovative strategies aimed at enhancing the effectiveness of TIL based therapy. In the present review, the developmental history of TIL based therapy was systematically summarized and analyzed, while also presenting a unique perspective on enhancing the multi dimensional anti tumor capabilities of TILs. The insight and conclusions presented in this review may contribute to improving the efficacy of TIL based therapy and expediting its development.
论文信息
- 作者
- Yu Z、Shi J、Fang Y、Zhao Y、Xu A、Li N
- 第一作者单位
- R&D, Qingdao Sino‑cell Biomedicine Co., Ltd., Qingdao, Shandong 266000, P.R. China.China
- 通讯作者单位
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.China
- 文献类型
- 综述
- 期刊
- Oncology reports2024 Jun
- 原文标识
- PubMed 38666543 · DOI 10.3892/or.2024.8744
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →